HAWTHORNE, N.Y.--(BUSINESS WIRE)--Sept. 8, 2006--Taro Pharmaceutical Industries Ltd. (“Taro,” NASDAQ: TARO) today reported that it has filed an Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration for Oxcarbazepine Tablets 150, 300 and 600 mg (“oxcarbazepine tablets”).
